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Summary In a study designed to compare response rates of patients with stage III epithelial ovarian
carcinoma to ifosfamide and carboplatin, 152 patients were randomised to receive either sequential therapy
with three cycles of ifosfamide followed by three cycles of carboplatin, or to six cycles of single agent
carboplatin. Ifosfamide was given every 3 weeks in a dose of 5 gm m2 as a 24h infusion with mesna,
1 gm m-2 by i.v. bolus prior to ifosfasmide, 3 gm m-2 with ifosfamide, and 1 gm m-2 as an 8 h infusion after
ifosfamide. Carboplatin was given in a dose of 400 mg m-2 by short i.v. infusion every 4 weeks. Sixty-eight
evaluable patients were randomised to sequential ifosfamide/carboplatin, and 67 to single agent carboplatin.
Median follow-up is 36 months (range 5.5-82.3). After three cycles of treatment two patients in the
ifosfamide/carboplatin arm achieved complete remission (CR), and 12 partial remission (PR) for an overall
response rate of 29%, whereas in the carboplatin arm ten patients achieved CR, and 23 PR, for an overall
response rate of 63% (P = 0.0008). Seven of 15 patients with progressive disease, and nine of 20 patients with
stable disease at the initial response evaluation, following three cycles ofifosfamide, subsequently responded to
carboplatin therapy so that the final response rate to the complete regimen was 65% for the ifosfamide/
carboplatin arm, compared to 71% for the carboplatin arm (NS). For the ifosfamide/carboplatin arm, median
recurrence free survival and overall survival were 14.1 months and 18.7 months. Corresponding figures for the
carboplatin arm were 14.5 months and 21.5 months (NS). Both treatments were generally well tolerated.
However 47% of patients in the ifosfamide/carboplatin arm developed alopecia sufficient to require a wig,
compared to only 2% in the carboplatin arm. Ifosfamide is clearly less effective, and more toxic than
carboplatin. Ifosfamide failures can however be effectively salvaged by subsequent carboplatin treatment.
Ifosfamide cannot be recommended for single agent therapy in ovarian carcinoma, however the combination
of carboplatin plus ifosfamide might be a suitable treatment to be tested in a future randomised study against
carboplatin alone.
Cisplatin has become established as the most important drug
in the chemotherapy of epithelial ovarian carcinoma (Thig-
pen et al., 1989). Unfortunately its use is complicated by
significant toxicity in the form of nausea and vomiting,
nephrotoxicity, peripheral neuropathy, and ototoxicity (Wilt-
shaw & Kroner, 1976; Wiltshaw et al., 1979; Bruckner et al.,
1981). Carboplatin, a recently developed analogue of cis-
platin has a different toxicity profile to the parent drug; its
dose limiting toxicity being haematological; nausea, vomiting,
nephrotoxicity and ototoxicity are much less of a problem
(Calvert et al., 1982; Evans et al., 1983). The two drugs have
been shown to produce equivalent response rates and sur-
vival in several randomised studies in ovarian cancer (Perren
et al., 1989; Mangioni et al., 1989; Adams et al., 1989) and
many groups have now adopted carboplatin as their first line
chemotherapy regimen.
Prior to the advent of cisplatin, ovarian carcinoma was
routinely treated with alkylating agents and indeed a ran-
domized study comparing a cisplatin containing combination
with chlorambucil showed no significant survival advantage
from the use of the cisplatin containing combination (Wil-
liams et al., 1985). Ifosfamide, an analogue of cyclophos-
phamide, first entered clinical trial in 1972 but its use was
complicated by the development of haemorrhagic cystitis
(Van Dyk et al., 1972; Bremner et al., 1974) and it was not
until the development of Mesna (Bryant et al., 1988) that
further evaluation became possible. It now seems clear that
ifosfamide has equivalent activity to that of cyclophospha-
mide in many diseases but causes significantly less myelosup-
pression (Brade et al., 1985). However, in ovarian carcinoma
there are some early studies published in the German litera-
ture suggesting response rates to ifosfamide in the order of
70-80% (Schnitker et al., 1976; Briihl et al., 1976). More
recent studies have shown a response rate of ifosfamide of
20% in patients who had failed cisplatin containing combina-
tion chemotherapy (Sutton et al., 1990), and a response rate
of 12% in 41 patients with true platinum resistant disease
(Markman et al., 1992).
The purpose of the study described in this paper was to
compare the response rate of ovarian cancer to ifosfamide
with that to carboplatin in previously untreated patients.
However, it was thought to be unethical to withhold a
platinum compound from early use in patients with advanced
stage ovarian carcinoma. Thus the patients were treated with
three courses of ifosfamide followed by three courses of
carboplatin, and response rate and survival to this therapy
were compared with six courses of carboplatin given in a
conventional manner.
Patients, materials and methods
Patients with suspected ovarian carcinoma underwent initial
surgery at their referring hospital. Where possible a total
abdominal hysterectomy, bilateral salpingo-oophorectomy
and omentectomy were performed, together with maximal
debulking of any further tumuor. Patients were then referred
to one of four hospitals for chemotherapy. Where possible
histological specimens were reviewed centrally. Prior to treat-
ment an abdominal and pelvic CT scan and ultrasound
examination were performed, usually within 4 weeks of the
primary surgery. Patients were staged on the basis of the
findings at operation, and on the results of ultrasound and
CT scan. Patients with FIGO stage III ovarian carcinoma
who had received no previous chemotherapy or radiotherapy
were eligible to enter the study. Patients were randomised by
telephoning the central trial office, randomisations had been
prepared at the outset of the study and were kept in number-
ed sealed envelopes. Patients entered the study between April
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1984 and April 1989. All patients entering the study gave
witnessed informed consent according to institutional guide-
lines.
Patients randomised to carboplatin received 400 mg m-2 of
this drug in 500 ml of 5% dextrose over 30 min repeated
every 28 days for six courses. Patients randomised to sequen-
tial ifosfamide/carboplatin received ifosfamide 5 gm2 as a
24 h infusion in three litres of dextrose saline with mesna
3 gm-2. Mesna
I gm-2 was given as an i.v. bolus before
starting the ifosfamide infusion, and repeated in a dose of
1 gm-2 over 8 h on completion of the ifosfamide infusion.
Ifosfamide was repeated every 3 weeks for three courses and
was then followed by three courses of carboplatin 400mg
m 2 every 4 weeks.
Patients in both arms of the study were evaluated for
clinical response immediately prior to the fourth course of
treatment and again 4 weeks after the sixth course of treat-
ment. On each occasion clinical examination was performed
together with a repeat CT scan and ultrasound scan of the
abdomen and pelvis. Second look laparotomy was performed
only on 36 patients whose initial surgery had been incomplete
and who appeared to have achieved a good response to
chemotherapy. Twenty-three patients with macroscopic resi-
dual disease inevaluable by CT or ultrasound scanning were
restaged by laparoscopy at the end of treatment. Patients in
either arm who had clinical evidence of progressive disease
after one or two cycles of treatment had full radiological
revaluation of their disease. If progressive disease was con-
firmed patients in the ifosfamide/carboplatin arm were
crossed over to carboplatin at that stage; patients in the
carboplatin arm were not crossed over to ifosfamide but
received further treatment with either chlorambucil, proges-
togens, or symptomatic care only as appropriate. Patients in
both arms of the study who had not yet achieved CR but
who were felt to be continuing to respond to completion of
the trial chemotherapy were eligible to continue therapy to a
maximum of five further cycles with a single platinum agent.
Renal function for patients in both arms of the study was
monitored by measurement of the glomerular filtration rate
(GFR) by 5"Cr labelled EDTA clearance at the start of
treatment and again after three and six courses. Haemato-
logical toxicity was monitored by measurement of the full
blood count prior to each course of treatment. If the pre-
treatment white cell count was less than 3 x 10 1` or the
platelet count less than 100 x I09 1- then chemotherapy was
delayed for 1 week. Routine nadir counts were not per-
formed.
Response and toxicity were measured according to WHO
criteria (World Health Organisation, 1992). Freedom from
relapse (for patients achieving complete response, partial res-
ponse, or who had no evaluable residual disease at the
initiation of chemotherapy) and survivals were measured
from the date of randomisation and were plotted using the
method of Kaplan and Meier (1958), differences between the
two curves were calculated according to the Log Rank test
(Peto et al., 1977). For the freedom from relapse analysis,
the maximum response status was used, so that a patient in
the sequential ifosfamide/carboplatin arm with progressive
disease after three cycles of ifosfamide but partial remission
after carboplatin would be classified as achieving PR. Multi-
variate analysis of survival data was performed using the Cox
proportional hazards regression model (Cox, 1972). Variables
included in the final model were selected using a forward
stepwise technique.
Results
One hundred and fifty-two patients were randomised into the
study between April 1984 and 1989. Seventeen patients were
subsequently excluded; 11 because review of the data sug-
gested that they did not in fact have Stage III disease; two
patients were randomised into the trial but then treated
according to a different protocol; one patient had received
previous chemotherapy; two patients were found on histology
review to have a pelvic sarcoma; and one patient was ran-
domised but refused treatment. A total of 135 patients were
therefore included in these analyses.
Sixty-seven patients were randomised to carboplatin and
68 patients to sequential ifosfamide/carboplatin. The median
follow-up for all patients is 36 months (range 5.5-82.3
months). Patient characteristics are shown in Table I and it
can be seen that patients were well balanced between the
arms with respect to age, extent of initial surgery, bulk of
residual disease after initial surgery, histological sub-type,
histological grade, and performance status at the start of
treatment.
Response
The results of the initial response evaluation are shown in the
upper part of Table II. For 64 patients in the carboplatin
Table I Patient characteristics
Median age (range)
Surgery
TAH + BSO + Oment
TAH + BSO
Suboptimal
Unknown
Residual disease
Zero
<2cm
2-5cm
>5cm
Histology
Serous
Mucinous
Endometrioid
Mesonephroid
Adenocarcinoma
Mixed tumours
Undifferentiated carcinoma
Unknown
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Unknown
Performance status
0
I
II
Unknown
Carboplatin
n = 67
59 (31-77)
36 (54%)
7 (10%)
24 (36%)
7 (10%)
20 (30%)
19 (28%)
21(31%)
39 (58%)
6 (9%)
5 (7%)
1(1.5%)
11(16%)
2 (3%)
1(1.5%)
2 (3%)
4 (6%)
16 (24%)
32 (48%)
15 (22%)
38 (57%)
19 (28%)
7 (10%)
3 (4%)
Ifosfamidel
carboplatin
n = 68
57 (28-73)
33 (49%)
3 (4%)
31(46%)
1 (1%)
4 (6%)
27 (40%)
12 (18%)
25 (37%)
39 (57%)
6 (9%)
9 (13%)
3 (4%)
8 (12%)
2 (3%)
0
1 (1%)
4 (6%)
16 (23%)
30 (44%)
18 (26%)
35 (51%)
22 (32%)
6 (9%)
5 (7%)
Table II Response according to randomised arm of treatment
A First response evaluationa
Not evaluable
Evaluable
CR
PR
NC
PD
CR + PR (95% CI) Evaluable
Carboplatin
15
52
10 (19%)
23 (44%)
12 (23%)
7 (13%)
63%b (49-76)
5
62
24 (39%)
20 (32%)
9 (14.5%)
9 (14.5%)
71% (58-82)
Ifos/Carbo
19
49
2 (4%)
12 (24%)
20 (41%)
15 (31%)
29%b(17-43)
Ifos/Carbo
6
62
15 (25%)
25 (41%)
10 (15%)
12 (20%)
65% (51 -76)
Not evaluable
Evaluable
CR
PR
NC
PD
CR + PR (95% CI) Evaluable
aInitial response was assessed after three cycles of chemotherapy,
except for three patients in the carboplatin arm and 11 patients in the
ifosfamide/carboplatin arm who had earlier response evaluation
because of clinical evidence of progressive disease. bp= 0.0008.
B Maximum response to the complete regimen
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arm and 56 patients in the ifosfamide/carboplatin arm this
evaluation was carried out after three cycles of treatment.
However three patients in the carboplatin arm and 11
patients in the ifosfamide/carboplatin arm had clinical evi-
dence of progressive disease before they had completed three
cycles of treatment and therefore had an earlier response
evaluation. One patient in the ifosfamide/carboplatin arm
was crossed over to carboplatin after only two cycles of
ifosfamide or domperidone. The number of courses of carbo-
platin and ifosfamide received according to randomised arm
of treatment are shown in Table III. Fifteen patients in the
platin and ifosfamide recieved according to randomised arm
of treatment are shown in Table III. Fifteen patients in the
carboplatin arm and 19 in the ifosfamide/carboplatin arm
were inevaluable at this stage; these were patients who either
had no residual disease at the end of their initial surgery or
whose residual disease could not be evaluated by CT scan or
clinical examination. Of 52 evaluable carboplatin patients,
ten (19%) achieved complete remission (CR), and 23 (44%)
achieved partial remission (PR). Of 49 evaluable ifosfamide/
carboplatin patients only two (4%) achieved CR and 12
(24%) PR after three courses of ifosfamide. Seven patients in
the carboplatin arm (13%) had progressive disease (PD)
compared with 15 (31%) in the ifosfamide/carboplatin arm.
The overall response rates (CR + PR divided by number of
evaluable patients) for the two arms were therefore 63%
(95% confidence intervals (CI): 49-76%) vs 29% (95% CI:
17-43%) - P=0.0008.
For the 12 patients in the carboplatin arm with stable
disease at the initial response evaluation, four subsequently
achieved PR with three further cycles of carboplatin and two
developed PD. In the remaining six the disease status remain-
ed unchanged. Of the 20 patients in the ifosfamide/carboplatin
arm with stable disease at the initial response evaluation one
subsequently achieved CR and eight PR with carboplatin
treatment, three patients developed PD and in eight the
disease status remained unchanged. Of the 15 patients in this
arm with PD after their first three cycles of ifosfamide, two
subsequently achieved CR and five PR with carboplatin. One
of these patients improved but not sufficiently to be classified
as PR and seven patients continued to have disease progres-
sion.
The lower part of Table II shows the maximum response
achieved to the regimen as a whole. Sixty-two patients in
each arm were evaluable for response. Five patients in the
carboplatin arm and six patients in the ifosfamide/carbo-
platin arm remained inevaluable because they had only
minimal residual disease following baseline surgery and did
not have a second look procedure. The overall response rate
to carboplatin was 71% (95% CI: 58-82%) and to ifosfa-
mide/carboplatin was 65% (95% CI: 51-76%). The CR rate
was higher in the carboplatin group than in the ifosfamide/
carboplatin group (39% vs 25%) but this difference was not
significant.
In both arms of the study some patients were still respond-
ing to therapy at the end of six courses and were continued
on a platinum compound for up to a further five treatments.
Eleven patients in the carboplatin arm received further
Table III Number of courses ofcarboplatin and ifosfamide received
according to randomised arm of treatment
Ifosfamide/carboplatin
Course no. Carboplatin Ifo Carbo
1 67 68 -
2 66 65 2
3 64 56 10
4 60 - 64
5 60 63
6 58 - 58
Total 375 189 197
Note: Patients who stopped, or changed treatment early did so
because ofdisease progression, with the exception ofone patient who
developed angioedema after two cycles ofifosfamide. This patient was
crossed over to carboplatin.
therapy and five patients changed from PR to CR as a result.
In the ifosfamide/carboplatin arm 15 patients in PR went on
to have further therapy and three patients changed to CR
status as a result.
Freedomfrom recurrence andsurvival
Curves for freedom from recurrence and for survival are
shown in Figures 1 and 2 respectively. Forty-five of49 (92%)
carboplatin patients have relapsed compared with 35 of 46
(76%) ifosfamide/carboplatin treated patients. Freedom from
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Figure 1 Freedom from relapse according to treatment arm,
measured from date of randomisation, for responding patients
and those with no evaluable residual disease after initial surgery.
( ) carboplatin, n = 49; (---) infosfamide/carboplatin, n =
46. Numbers of patients at risk are also shown.
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Figure 2 Survival from date of randomisation according to
treatment arm for all patients. ( ) carboplatin, n = 67; (---)
ifosfamide/carboplatin, n = 68. Numbers of patients at risk are
also shown.
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recurrence curves were, however, virtually superimposable.
Median recurrence free period was 14.5 months for carbo-
platin and 14.1 months for ifosfamide/carboplatin. Fifty-four
of the 67 (81%) carboplatin patients have died compared
with 52 of the 68 (76%) ifosfamide/carboplatin treated
patients. Median survival for carboplatin treated patients was
21.5 months and for ifosfamide/carboplatin patients was 18.7
months (P>0.1), 5 year survival for the two arms was
18.5% and 17.5% respectively. For patients achieving CR, or
who had no evaluable residual disease at both the initial and
final response evaluation, median survival and 5 year survival
were 32.4 months and 30% respectively for patients in the
carboplatin arm; corresponding figures for the ifosfamide/
carboplatin arm were 21.6 months and 40%.
A multivariate analysis of the survival data showed that
the independent factors predicting for good survival were
residual disease of 5 cm or less in greatest bulk and WHO
performance status grade 0 to 1. Treatment arm was not a
significant independent factor even after correction for these
two variables.
Toxicity
Toxicity data are shown in Table IV. Both treatments were
well tolerated with no significant difference between the arms
in terms of the number ofpatients experiencing severe nausea
and vomiting or infection. Haematological toxicity was
generally mild with only six patients in the carboplatin arm,
and five patients in the ifosfamide/carboplatin arm having
persistant grade 3/4 leucopenia, at the time that the next
cycle of treatment was due. Neutropenic sepsis was not seen
in either arm. Corresponding figures for grade 3/4 thrombo-
cytopenia were one and 0 patients in the two arms respec-
tively. For anaemia, seven patients in the carboplatin arm
developed grade 3/4 toxicity compared with only one in the
ifosfamide/carboplatin arm, but this difference did not
achieve statistical significance.
Within the ifosfamide/carboplatin arm there was no differ-
ence in the incidences of toxicities between courses 1-3 and
4-6 (data not shown). There was however the expected
marked difference between the two treatment regimens in
terms of the number of patients with grade 3/4 alopecia. For
the carboplatin arm only one patient developed alopecia
sufficient to require a wig, compared with 26 (47%) of the
patients in the ifosfamide/carboplatin arm. A significant pro-
portion of patients treated in this arm started to regrow their
hair during the second phase of treatment with carboplatin.
Renal toxicity was evaluated on the basis of changes,
compared to baseline, in the GFR after three and after six
courses of treatment. Overall there was no significant change
in GFR with treatment in either arm of the study.
Discussion
The results of this study clearly demonstrate that ifosfamide
is inferior to carboplatin in terms of the proportion of
patients with FIGO stage III epithelial ovarian carcinoma
who respond to the two drugs. When assessed after three
courses of treatment only 14 patients randomised to ifosfa-
mide had responded (29%) compared to 33 (63%) of those
randomised to carboplatin. In addition only two of the 14
patients randomised to ifosfamide had achieved a CR (4%)
compared to ten patients randomised to carboplating (19%).
Patients with ifosfamide resistance were however effectively
salvaged by subsequent carboplatin treatment.
Our data do not support the early German data (Schnitker
et al., 1976; Briihl et al., 1976) which suggested response rates
to single agent ifosfamide of up to 79%. One explanation for
the difference in response rates might be that both of the
German studies used very high doses ofifosfamide. However,
it should be noted that interpretation of these studies is
limited by the fact that details of prognostic factors were not
given, and in one of the studies (Schnitker et al., 1976) the
extent of previous treatment and the proportion of patients
with measurable disease is unclear.
The results of our study, showing a response rate of 29%
after three courses of ifosfamide are in line with the single
agent response rates reported with many single alkylating
agents therapies such as chlorambucil, melphalan or cyclo-
phosphamide (Thigpen et al., 1989; Williams et al., 1985;
Omura et al., 1983). The fact that ifosfamide failures were
effectively salvaged by the subsequent use of carboplatin also
finds support in the literature and many studies have shown
that patients resistant to alkylating agents can be salvaged by
subsequent treatment with a platinum agent (Wiltshaw &
Kroner, 1976; Bruckner et al., 1981; Williams et al., 1985). It
is interesting to note that despite the use of initial ifosfamide,
with its significantly poorer response rate and significantly
higher proportion of patients with primary resistant disease,
that the final response rate to ifosfamide/carboplatin was
virtually identical to that achieved by carboplatin alone (71%
vs 65%) (95% confidence intervals shown in Table II) which
suggests that platinum resistance is not fully induced by prior
exposure to ifosfamide, even in patients resistant to this drug.
It should however be noted that although the final response
rates in the two arms were virtually identical there was a
lower proportion of complete remissions in the ifosfamide/
carboplatin arm than in the carboplatin arm (25% vs 39%).
There did not however appear to be any difference between
the two arms of the study in the progression free period as
measured from the date of randomisation; neither was there
any significant difference between the arms in terms of sur-
vival. However, this study is relatively small and has limited
power to detect a difference in survival and it may be that a
larger study would show a significant difference between the
two arms. The median survival of 21.5 months for carbo-
platin and 18.5 months for ifosfamide/carboplatin are consis-
tent with the 23 months and 19.5 months seen in two
previous trials carried out by our group with single agent
platinum therapy in stage III ovarian carcinoma (Perren et
al., 1989; Wiltshaw et al., 1986).
The fact that some of the patients in each arm of the study
Table IV Toxicity - Worst toxicity experienced at any time during treatment table shows the number (percent) ofpatients who experienced the
indicated toxicity and grade
Carboplatin Ifos/Carbo
WHO Toxicity Grade 0 1 2 3/4 0 1 2 3/4
Haematological (n = 63)a (n = 56)
Anaemia 25 (40%) 22 (35%) 9 (14%) 7 (11%) 28 (50%) 19 (34%) 8 (14%) 1 (2%)
Leukopenia 21 (33%) 20 (32%) 16 (25%) 6 (10%) 21 (38%) 13 (23%) 17 (30%) 5 (9%)
Thrombocytopenia 52 (82%) 4 (6%) 6 (10%) 1 (2%) 53 (95%) 1 (2%) 2 (3%) 0 (0%)
Non-haematological (n = 49) (n = 55)
Nausea and vomiting 5 (11%) 5 (10%) 29 (59%) 10 (20%) 11 (20%) 11 (20%) 22 (40%) 11 (20%)
Alopecia 35 (72%) 10 (20%) 3 (6%) 1 (2%) 12 (22%) 5 (9%) 12 (22%) 26 (47%)
Neuropathy 40 (82%) 9 (18%) 0 (0%) 0 (0%) 49 (87%) 6 (11%) 1 (2%) 0 (0%)
Infection 43 (88%) 5 (10%) 1 (2%) 0 (0%) 45 (82%) 7 (13%) 3 (5%) 0 (0%)
Diarrhoea 41 (84%) 6 (12%) 2 (4%) 0 (0%) 48 (87%) 5 (9%) 2 (4%) 0 (0%)
Stomatitis 38 (78%) 8 (16%) 3 (6%) 0 (0%) 48 (87%) 1 (2%) 6 (11%) 0 (0%)
aHaematological toxicity based on blood counts taken prior to each cycle of treatment. bp = 0.08. cp = <0.0001.1194 T.J. PERREN et al.
continued to show disease regression for up to 11 courses of
treatment suggests that, in patients with sensitive tumours, 6
months of therapy, at orthodox doses, may not be sufficient
to get the full benefit from cytotoxic drugs given as single
agents.
In terms of toxicity, there was a clear difference between
the two arms with respect to alopecia. Only one patient
treated with carboplatin required a wig compared with 26
(47%) in the ifosfamide arm. This difference in toxicity was
particularly marked and of great importance to the patients.
Indeed several patients eligible for the study refused ran-
domisation after learning of this difference in toxicity profile,
preferring to be treated instead with cisplatin outside of the
trial despite the toxicity profile of this drug being explained
in detail. There was however no significant difference between
the arms in terms of nausea and vomiting, or the rate of
infections which was very low in both arms of treatment.
There was no overall evidence of significant renal toxicity in
either arm of the study. While some patients did show indi-
vidual changes in GFR during treatment this was never felt
to be clinically important and often improved without further
intervention. This fits with our experience with high dose
carboplatin in patients with stage IV ovarian carinoma
(Hardy et al., 1990). An additional factor which makes ifos-
famide treatment less acceptable is that it is more difficult to
give and patients usually require two nights in hospital,
whereas, carboplatin can commonly be given in the out
patients setting.
In conclusion, although ifosfamide has activity in patients
with FIGO stage III ovarian carcinoma. It is clearly less
active and more toxic than carboplatin and for these reasons
it cannot be recommended as single agent therapy for this
group of patients. It is however a drug with activity in
ovarian carcinoma as shown by the 29% response rate
achieved after three cycles of treatment with this drug. We
have shown previously that ifosfamide can be given in con-
junction with carboplatin (Gallagher et al., 1989). A recent
literature overview of chemotherapy for ovarian cancer (Peto
& Easton, 1989) and a meta analysis of published and
unpublished randomised trials (Advanced Ovarian Cancer
Trialists Group, 1991) suggests that the use of a cisplatin
containing combination may result in a small but significant
survival advantage compared to the use of cisplatin alone.
Carboplatin plus ifosfamide might be a suitable combination
to be tested in a future randomised study against carboplatin
alone.
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